Certain nucleoside analog reverse transcriptase inhibitor (NRTI) antiretroviral drugs used to treat human immunodeficiency virus (HIV) infection lead to accelerated accumulation of somatic mitochondrial DNA (mtDNA) mutations.
Results | The clinicopathological characteristics are summarized in the Table. Patient 1 presented with progressive ataxia, with a background of sensorineural deafness and insulindependent diabetes mellitus with associated nephropathy requiring continuous ambulatory peritoneal dialysis. At the time of referral, HIV infection was treated with didanosine, lamivudine, and nevirapine for 8 years. Following assessment, didanosine was switched to abacavir. Magnetic resonance imaging of the brain revealed volume loss and periventricular and deep white matter signal change; however, these features were generalized rather than localized to the cerebellum. Proton magnetic resonance spectroscopy findings of the brain were normal. Sequential cytochrome C oxidase (COX)-succinate dehydrogenase (SDH) histochemical reactions revealed 30% COX-deficient fibers with approximately 10% of fibers showing SDH hyperintensity, suggestive of mitochondrial proliferation ( Figure) . Molecular analyses of skeletal muscle mtDNA showed increased mtDNA copy number and evidence of multiple mtDNA deletions amplified by long-range polymerase chain reaction assays.
2 A screen of nuclear genes (POLG, POLG2, PEO1, RRM2B, SLC25A4, and TK2) associated with mtDNA maintenance disorders revealed no mutations. Patients 2, 3, and 4 presented with myalgia, with or without mildly elevated creatine kinase (patient 2, 564 IU/L; patient 3, 841 IU/L; and patient 4, normal <320 IU/L; to convert serum creatine kinase to microkatals per liter, multiply by 0.0167). All had extensive past antiretroviral exposure including multiple polymerase γ-inhibiting NRTIs.
3 Findings from nerve conduction studies revealed mild axonal sensorimotor neuropathy. Cytochrome C oxidase-SDH histochemistry revealed mosaic patterns (15%, 12%, and 1% for patients 2, 3, and 4, respectively) of COX deficiency. Phosphorus magnetic resonance spectroscopy of soleus muscle was performed in patients 3 and 4 and showed significant reduction in the maximal rate of postexertional adenosine triphosphate resynthesis. On molecular analy- ses (patients 3 and 4), mtDNA copy number in muscle was normal but large-scale mtDNA deletions were detected (not shown).
Discussion | We describe 4 adults with treated HIV infection and evidence of mitochondrial dysfunction. Patients 1, 2, and 3 had significant levels of COX-deficient skeletal muscle fibers consistent with mitochondrial myopathy. Although the overall frequency of COX-deficient fibers in patient 4 was low, the presence of somatic mtDNA mutations and abnormal muscle bioenergetics suggests he also had a mild mitochondrial myopathy. What is the likely cause of these findings? Given that mitochondrial disorders presenting in adult life are rare (approximately 1 in 10 000), 4 it seems likely that the patients we described have an iatrogenic disorder caused by earlier exposure to polymerase γ-inhibiting NRTIs. Although we cannot wholly exclude the possibility of a 2-hit model of NRTI exposure and a predisposing nuclear genetic defect of mtDNA maintenance, an extensive search for causative mutations in the most severely affected case failed to find a cause. In all cases, the observed mtDNA defect comprised mtDNA deletions rather than an mtDNA depletion as reported historically.
5 This argues for the importance of previous rather than current NRTI exposure. 1 Therefore, we suggest that in HIVinfected patients presenting with neuromuscular symptoms, the possibility of an acquired mitochondrial defect should continue to be considered in those patients with a relevant treatment history. Those patients with historical exposure to the polymerase γ-inhibiting dideoxynucleoside analogs are particularly worthy of further investigation. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Oxidative enzyme histochemistry, including cytochrome C oxidase (A, original magnification ×10) and cytochrome C oxidase-succinate dehydrogenase (B, original magnification ×10) reactions in patient 1 (P), reveals numerous cytochrome C oxidase-deficient, ragged-red fibers. C, The 9.9-kb and 16.0-kb long-range polymerase chain reaction assays confirm the presence of multiple mitochondrial DNA deletions and loss of full-length, wild-type mitochondrial DNA molecules in patient 1 muscle compared with an age-matched control (C) individual. 2 Previous work on the modeling of nondeterministic processes in MS development (random perturbations and time can amplify the effects of weak genetic and environmental factors) 3 may provide a conceptual framework to interpret a timing effect of vaccines on neuroinflammation.
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The fact that vaccinations of any type may represent a risk for short-term neuroinflammation is in keeping with previous results showing that, at least for environmental risk factors of viral origin, gene-environment interactions predispose to disease through perturbations that can be pathogen specific but also extensively shared by different viruses.
4
A further level of complexity is the potential beneficial effect of the Bacille Calmette-Guérin vaccine in early MS and individuals with a first demyelinating episode, 5 which may seem paradoxical considering the supposed relationship between adjuvanticity and autoimmunity. The mechanisms underlying immunomodulatory effects of Bacille Calmette-Guérin in neuroinflammation are not fully defined: the possibility that adjuvant immunotherapy may counteract a pathogenic loop due to Epstein-Barr virus (a known nonheritable risk factor in MS), involving Notch-1 signaling and Epstein-Barr nuclear antigen 2, suggests differences between benign exposure to microbes (as in most vaccinations) and infections in preventing or triggering immunopathology, respectively. Waiting for the disentanglement of all these levels of complexities, we endorse the authors' conclusion that no changes in vaccination policy are currently justified (rather, vaccines can even contribute to counteract the deficit of benign exposure to microbes that characterizes westernization and is strongly suspected of having favored the increased incidence of immunopathology in recent decades). However, vaccine procedures are potentially capable of activating (auto)immune effectors in patients with MS with sustained disease activity, as well as in individuals at risk (eg, in persons with radiologically isolated syndromes or in relatives of patients with predisease state). These conditions may be disclosed by a prevaccination contrast-enhanced magnetic resonance imaging of the brain and may deserve a postponement of vaccination even in case of subclinical signs of neuroinflammation.
